[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Epidemiology Forecast–2028

September 2019 | 100 pages | ID: H8C2CB623B0EN
DelveInsight

US$ 2,600.00 US$ 3,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 hours

DelveInsight’s ‘Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Epidemiology Forecast–2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017–2028

Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Disease Understanding

HR-positive/HER2-negative breast cancer is the most common form of breast cancer. This type accounts for a higher percentage of all breast cancers. Hormone receptors are proteins that receive hormone signals and tell the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. If cancerous cells get signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Addition to this, there is another factor which is also responsible for breast cancer which is known as human epidermal growth factor receptor 2 (HER2). Human epidermal growth factor receptor-2 is a gene that helps control how cells grow, divide, and repair themselves. There are more number of cases for breast cancer in women observed in comparison to the men.

Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Epidemiology

The HR-positive/HER2-negative epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of Breast Cancer in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the 7MM and Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the 7MM] of HR-positive/HER2-negative in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight’s epidemiology model for HR-positive/HER2-negative Breast Cancer has assessed that total incident population of Breast Cancer in the 7MM is expected to grow at CAGR of 0.83%, during study period [2017–2028]. DelveInsight’s estimate suggests the United States show higher incidence of Breast Cancer. As per the DelveInsight’s estimation, in 2017, among the EU-5 countries, Spain has the least number of breast cancer incident cases. According to the DelveInsight’s analyst, among the 7MM countries, Japan accounts for the second highest breast cancer incident cases.

In addition to this according to DelveInsight’s epidemiology model, based on the menopausal status of women suffering from breast cancer, in the 7MM, the higher number of cases were observed for the postmenopausal Breast cancer, accounting for 70–80% of the cases, while premenopausal women contributed a significantly lesser proportion of the patients. DelveInsight’s estimates suggests that based on stage-specific incidence of breast cancer in postmenopausal women, Stage IIIb,c and IV-specific breast cancer were observed to be less in number of patients. On the other hand, Stage I-IIIa together accounted for majority of the patient pool.

REPORT SCOPE
  • The report covers detailed overview of HR-positive/HER2-negative Breast Cancer explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of HR-positive/HER2-negative Breast Cancer
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of HR-positive/HER2-negative Breast Cancer in the 7MM
Catheter-related Bloodstream Infections Report Key Strengths
  • 10 Year Forecast of HR-positive/HER2-negative Breast Cancer epidemiology
  • 7MM Coverage
  • Total Incidence of Breast Cancer
  • Incidence of Breast Cancer Cases by Menopausal Status
  • Incidence of Breast Cancer Cases by Menopausal Status
  • Stage Specific Incidence of Breast Cancer in Post-Menopausal Women
  • Stage Specific Incidence of Breast Cancer in Post-Menopausal Women
  • Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype
  • Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype
Catheter-related Bloodstream Infections Report Assessment
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
1. KEY INSIGHTS

2. HORMONE RECEPTOR (HR)-POSITIVE/ HUMAN EPIDERMAL RECEPTOR 2 (HER2)-NEGATIVE BREAST CANCER EPIDEMIOLOGY OVERVIEW AT A GLANCE

2.1. Total Epidemiology Distribution of HR-positive/HER2-negative in 2017
2.2. Total Epidemiology Distribution of HR-positive/HER2-negative in 2028

3. DISEASE BACKGROUND AND OVERVIEW: HORMONE RECEPTOR (HR)-POSITIVE/ HUMAN EPIDERMAL RECEPTOR 2 (HER2)-NEGATIVE BREAST CANCER

3.1. Introduction
3.2. Types of Breast Cancer
  3.2.1. Subtypes of Breast Cancer
  3.2.2. Molecular Subtypes of Breast Cancer
3.3. Estrogen Receptor (ER)-Positive Breast Cancer
  3.3.1. Estrogen Receptor
  3.3.2. Estrogen Receptor 1 Mutations
3.4. Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer
  3.4.1. Role of Estrogen Receptor Alpha (ER?) in Regulating Breast Cancer Metabolism
3.5. Symptoms of HR-Positive Breast Cancer
3.6. Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer
3.7. Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer
3.8. Diagnostic Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer
  3.8.1. American Society of Clinical Oncology (ASCO)

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Total Incidence of Breast Cancer in the 7MM
4.4. Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM
4.5. Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
4.6. Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM

5. COUNTRY WISE-EPIDEMIOLOGY OF HORMONE RECEPTOR (HR) POSITIVE BREAST CANCER

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Total Incidence of Breast Cancer in the United States
  5.1.3. Incidence of Breast Cancer Cases by Menopausal Status in the United States
  5.1.4. Stage-Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States
  5.1.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States
  5.1.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States
  5.1.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States
5.2. EU5 Countries
5.3. Germany
  5.3.1. Assumptions and Rationale
  5.3.2. Total Incidence of Breast Cancer in Germany
  5.3.3. Incidence of Breast Cancer Cases by Menopausal Status in Germany
  5.3.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany
  5.3.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany
  5.3.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Germany
  5.3.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Germany
5.4. France
  5.4.1. Assumptions and Rationale
  5.4.2. Total Incidence of Breast Cancer in France
  5.4.3. Incidence of Breast Cancer Cases by Menopausal Status in France
  5.4.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France
  5.4.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France
  5.4.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France
  5.4.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France
5.5. Italy
  5.5.1. Assumptions and Rationale
  5.5.2. Total Incidence of Breast Cancer in Italy
  5.5.3. Incidence of Breast Cancer Cases by Menopausal Status in Italy
  5.5.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy
  5.5.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy
  5.5.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy
  5.5.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy
5.6. Spain
  5.6.1. Assumptions and Rationale
  5.6.2. Total Incidence of Breast Cancer in Spain
  5.6.3. Incidence of Breast Cancer by Menopausal Status in Spain
  5.6.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain
  5.6.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain
  5.6.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause Cases by Molecular Subtype in Spain
  5.6.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause Cases by Molecular Subtype in Spain
5.7. The United Kingdom
  5.7.1. Assumptions and Rationale
  5.7.2. Total Incidence of Breast Cancer in the United Kingdom
  5.7.3. Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom
  5.7.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom (2017–2028)
  5.7.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom
  5.7.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom
  5.7.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom
5.8. Japan
  5.8.1. Assumptions and Rationale
  5.8.2. Total Incidence of Breast Cancer in Japan
  5.8.3. Incidence of Breast Cancer Cases by Menopausal Status in Japan
  5.8.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028)
  5.8.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan
  5.8.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Japan
  5.8.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Japan

6. APPENDIX

6.1. Report Methodology

7. DELVEINSIGHT CAPABILITIES

8. DISCLAIMER

9. ABOUT DELVEINSIGHT

LIST OF TABLES

Table 1: Total Incidence of Breast Cancer in the 7MM (2017–2028)
Table 2: Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028)
Table 3: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Table 4: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Table 5: Total Incidence of Breast Cancer in the United States (2017–2028)
Table 6: Incidence of Breast Cancer by Menopausal Status in the United States (2017–2028)
Table 7: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Table 8: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Table 9: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028)
Table 10: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028)
Table 11: Incidence of Breast Cancer in Germany (2017–2028)
Table 12: Incidence of Breast Cancer by Menopausal Status in Germany (2017–2028)
Table 13: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Table 14: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Table 15: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028)
Table 16: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028)
Table 17: Total Incidence of Breast Cancer in France (2017–2028)
Table 18: Incidence of Breast Cancer by Menopausal Status in France (2017–2028)
Table 19: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Table 20: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Table 21: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028)
Table 22: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028)
Table 23: Total Incidence of Breast Cancer in Italy (2017–2028)
Table 24: Incidence of Breast Cancer by Menopausal Status in Italy (2017–2028)
Table 25: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Table 26: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Table 27: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028)
Table 28: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028)
Table 29: Total Incidence of Breast Cancer in Spain (2017–2028)
Table 30: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2028)
Table 31: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Table 32: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Table 33: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028)
Table 34: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028)
Table 35: Total Incidence of Breast Cancer in the United Kingdom (2017–2028)
Table 36: Incidence of Breast Cancer by Menopausal Status in the United Kingdom (2017–2028)
Table 37: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Table 38: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Table 39: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Table 40: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Table 41: Total Incidence of Breast Cancer in Japan (2017–2028)
Table 42: Incidence of Breast Cancer by Menopausal Status in Japan (2017–2028)
Table 43: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028)
Table 44: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan (2017–2028)
Table 45: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)
Table 46: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)

LIST OF FIGURES

Figure 1: Molecular Subtypes of Breast Cancer
Figure 2: Working of Estrogen Receptor
Figure 3: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains.
Figure 4: ER pathway and mechanisms of resistance. Estrogen-bound estrogen receptor (ER), in association with a variety of coactivators and co-repressors, exerts its classical genomic action as a transcription factor through the estrogen response element (ERE) of target genes.
Figure 5: Metabolism of Estrogen Receptor-Positive Breast Cancer
Figure 6: Lifestyle-related Breast Cancer Risk Factors
Figure 7: Diagnosis of ER-Positive Breast Cancer
Figure 8: Assays for Measuring Estrogen and Progesterone Receptor
Figure 9: Essential Elements Required for Accurate Testing of ERa And PGr Status In Breast Cancer by Immunohistochemistry.
Figure 10: Total Incidence of Breast Cancer in the 7MM (2017–2028)
Figure 11:Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028)
Figure 12: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Figure 13: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Figure 14: Total Incidence of Breast Cancer in the United States (2017–2028)
Figure 15: Incidence of Breast Cancer Cases by Menopausal Status in the United States (2017–2028)
Figure 16: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Figure 17: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Figure 18: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028)
Figure 19: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028)
Figure 20: Total Incidence of Breast Cancer in Germany (2017–2028)
Figure 21: Incidence of Breast Cancer Cases by Menopausal Status in Germany (2017–2028)
Figure 22: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Figure 23: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Figure 24: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028)
Figure 25: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028)
Figure 26: Total Incidence of Breast Cancer in France (2017–2028)
Figure 27: Incidence of Breast Cancer Cases by Menopausal Status in France (2017–2028)
Figure 28: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Figure 29: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Figure 30: Diagnosed Incidence of early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in France (2017–2028)
Figure 31: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in France (2017–2028)
Figure 32: Total Incidence of Breast Cancer in Italy (2017–2028)
Figure 33: Incidence of Breast Cancer Cases by Menopausal Status in Italy (2017–2028)
Figure 34: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Figure 35: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Figure 36: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Italy (2017–2028)
Figure 37: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Italy (2017–2028)
Figure 38: Total Incidence of Breast Cancer in Spain (2017–2028)
Figure 39: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2028)
Figure 40: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Figure 41: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Figure 42: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal Cases by Molecular Subtype in Spain (2017–2028)
Figure 43: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal Cases by Molecular Subtype in Spain (2017–2028)
Figure 44: Total Incidence of Breast Cancer in the United Kingdom (2017–2028)
Figure 45: Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom (2017–2028)
Figure 46: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Figure 47: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Figure 48: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Figure 49: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Figure 50: Total Incidence of Breast Cancer in Japan (2017–2028)
Figure 51: Incidence of Breast Cancer Cases by Menopausal Status in Japan (2017–2028)
Figure 52: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan2017–2028)
Figure 53: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan (2017–2028)
Figure 54: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)
Figure 55: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)


More Publications